18.90
+0.49(+2.66%)
Currency In USD
| Previous Close | 19.43 |
| Open | 19.54 |
| Day High | 20.08 |
| Day Low | 19.04 |
| 52-Week High | 29.16 |
| 52-Week Low | 16.8 |
| Volume | 231,129 |
| Average Volume | 386,655 |
| Market Cap | 1.05B |
| PE | -17.39 |
| EPS | -1.15 |
| Moving Average 50 Days | 19.93 |
| Moving Average 200 Days | 19.93 |
| Change | 0.57 |
If you invested $1000 in Akoustis Technologies, Inc. (AKTS) 10 years ago, it would be worth $12,193.55 as of February 25, 2026 at a share price of $18.9. Whereas If you bought $1000 worth of Akoustis Technologies, Inc. (AKTS) shares 5 years ago, it would be worth $1,296.3 as of February 25, 2026 at a share price of $18.9.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Data not available
Aktis Oncology to Present at Upcoming March Investor Conferences
GlobeNewswire Inc.
3 hours ago
BOSTON, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (NASDAQ:AKTS), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addre
Aktis Oncology Receives U.S. FDA Fast Track Designation for AKY-1189, a Nectin-4 Miniprotein Radioconjugate
GlobeNewswire Inc.
11 hours ago
U.S. FDA Fast Track designation granted to AKY-11891 for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have progressed on or after prior systemic therapiesOngoing Phase 1b trial of AKY-1189 enrolling patien
Aktis Oncology Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
GlobeNewswire Inc.
Jan 13, 2026 11:30 AM GMT
BOSTON, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (“Aktis”), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed